Live Marvell Technology Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow CERO THERAPEUTICS HOLDINGS, INC.

Get SEC filing alerts via email and in your feed for CERO THERAPEUTICS HOLDINGS, INC.

CERO CEROW

CERO THERAPEUTICS HOLDINGS, INC.

About CERO THERAPEUTICS HOLDINGS, INC.

Cero Therapeutics develops innovative engineered T cell therapies for cancer, focusing on both hematological malignancies and solid tumors. Its platform integrates innate and adaptive immune functions into CER-T cells, targeting tumor-specific antigens like TIM-4-L. The company's lead candidate, CER-1236, aims to enhance tumor clearance via cytotoxic, phagocytic, and antigen presentation mechanisms, leveraging well-established CAR-T manufacturing processes for broad cancer treatment applications.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from CERO THERAPEUTICS HOLDINGS, INC.

1
1
CERO THERAPEUTICS HOLDINGS, INC. Cero Therapeutics Reports $5.9 Million Net Loss and Faces Funding Challenges in Q1 2026

Via official filing (AI summary) | 23 days ago | 0 comments

2
1
CERO THERAPEUTICS HOLDINGS, INC. CERo Therapeutics Reports $19.9 Million Net Loss and Financial Results for Fiscal Year 2025

Via official filing (AI summary) | about 2 months ago | 0 comments

3
1
CERO THERAPEUTICS HOLDINGS, INC. Cero Therapeutics Reports $15.4 Million Net Loss and Seeks Additional Funding

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
CERO THERAPEUTICS HOLDINGS, INC. Cero Therapeutics Reports $30.1 Million Net Loss and Progress in Clinical Trials

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
CERO THERAPEUTICS HOLDINGS, INC. Cero Therapeutics Reports $5.1 Million Net Loss and Increased R&D Expenses for Q1 2025

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
CERO THERAPEUTICS HOLDINGS, INC. CERo Therapeutics Reports $8.3 Million Net Loss for 2024 Amid Increased R&D Expenses

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
CERO THERAPEUTICS HOLDINGS, INC. CERo Therapeutics Holdings Reports Financial Changes Following Merger, Seeks Additional Capital

Via official filing (AI summary) | over 1 year ago | 0 comments